Cross-Sector entity
CSL Seqirus is most often covered alongside Arcturus Therapeutics, which appears in 2 of these 4 stories. That works out to roughly 2.2 stories per week across a 13-day span. The busiest single day carried 2. pharma accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder.
4 verified stories tracked
Last mentioned: Mar 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CSL Seqirus is most often covered alongside Arcturus Therapeutics, which appears in 2 of these 4 stories. That works out to roughly 2.2 stories per week across a 13-day span. The busiest single day carried 2. pharma accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. Each carries 2 original sources on average. This profile follows 4 Cross-Sector stories mentioning CSL Seqirus across the period from March 2, 2026 to March 14, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CSL Seqirus. Shared-story counts are live from our verified record — not editorial picks.
Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Source: abc11.com · abc7ny.com
Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
